Historique
Périodique
Reductions in HIV risk behaviors among depressed drug injectors
(Réductions des conduites à risque vis-à-vis du VIH chez des usagers de drogues par injection déprimés.)
Auteur(s) :
M. D. STEIN ;
B. J. ANDERSON ;
SOLOMON D. A. ;
B. H. HERMAN ;
S. E. RAMSEY ;
R. A. BROWN ;
I. W. MILLER
Article en page(s) :
417-432
Refs biblio. :
26
Domaine :
Drogues illicites / Illicit drugs
Langue(s) :
Anglais
Discipline :
MAL (Maladies infectieuses / Infectious diseases)
Thésaurus mots-clés
USAGER
;
INJECTION
;
VIH
;
REDUCTION DES RISQUES ET DES DOMMAGES
;
DEPRESSION
;
PSYCHOTHERAPIE
;
ANTIDEPRESSEURS
;
EFFICACITE
Note générale :
American Journal of Drug and Alcohol Abuse (The), 2005, 31, (3), 417-432
Note de contenu :
tabl.
Résumé :
ENGLISH :
Objective: To determine if, by reducing depressive symptoms, combined psychotherapy and pharmacotherapy reduces HIV drug risk behavior compared to an assessment-only condition for active drug injectors over 9 months. Design: Randomized controlled trial. Setting: Outpatient academic research office. Patients: Active injection drug users with a DSM-IV diagnosis of major depression, dysthymia, substance-induced mood disorder with depressive features persisting for at least 3 months, or major depression plus dysthymia. In addition, participants had a Hamilton Rating Scale for Depression (MHRSD) score > 13. Intervention: Psychotherapy (8 sessions of cognitive behavioral therapy) plus antidepressant pharmacotherapy over 3 months. Main Outcome Measures: HIV Risk Assessment Battery (RAB) drug scale scores measured at three, six and nine months, and depression remission (MHRSD score = 8). Results: Participants (n = 109) were 64% male, 82% Caucasian, with a mean baseline MHRSD score of 20.7. Depression subtypes included major depression only (63%), substance-induced depression (17%), and double-depression (17%). Overall, study retention at nine months was 89%. Reported HIV drug risk scores decreased sharply over the first 3 months and continued to decline throughout the follow-up period. Between group differences were not significant in the intention-to-treat analysis. However, highly adherent participants had significantly lower HIV drug risk scores at 3 months (p
ENGLISH :
Objective: To determine if, by reducing depressive symptoms, combined psychotherapy and pharmacotherapy reduces HIV drug risk behavior compared to an assessment-only condition for active drug injectors over 9 months. Design: Randomized controlled trial. Setting: Outpatient academic research office. Patients: Active injection drug users with a DSM-IV diagnosis of major depression, dysthymia, substance-induced mood disorder with depressive features persisting for at least 3 months, or major depression plus dysthymia. In addition, participants had a Hamilton Rating Scale for Depression (MHRSD) score > 13. Intervention: Psychotherapy (8 sessions of cognitive behavioral therapy) plus antidepressant pharmacotherapy over 3 months. Main Outcome Measures: HIV Risk Assessment Battery (RAB) drug scale scores measured at three, six and nine months, and depression remission (MHRSD score = 8). Results: Participants (n = 109) were 64% male, 82% Caucasian, with a mean baseline MHRSD score of 20.7. Depression subtypes included major depression only (63%), substance-induced depression (17%), and double-depression (17%). Overall, study retention at nine months was 89%. Reported HIV drug risk scores decreased sharply over the first 3 months and continued to decline throughout the follow-up period. Between group differences were not significant in the intention-to-treat analysis. However, highly adherent participants had significantly lower HIV drug risk scores at 3 months (p
Affiliation :
Division General Internal Medicine, Rhode Island Hospital, 593 Eddy St., Providence, RI 02903. E-mail: msteinlifespan.org
Etats-Unis. United States.
Etats-Unis. United States.
Exemplaires
| Disponibilité |
|---|
| aucun exemplaire |